Connor, Clark & Lunn Investment Management (CC&L)’s Protalix BioTherapeutics PLX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $734K | Buy |
496,216
+13,341
| +3% | +$19.7K | ﹤0.01% | 1142 |
|
|
2025
Q1 | $1.24M | Buy |
+482,875
| New | +$1.24M | 0.01% | 882 |
|
|
2024
Q1 | – | Sell |
-70,990
| Closed | -$126K | – | 1677 |
|
|
2023
Q4 | $126K | Sell |
70,990
-96,546
| -58% | -$172K | ﹤0.01% | 1301 |
|
|
2023
Q3 | $278K | Buy |
167,536
+51,997
| +45% | +$86.3K | ﹤0.01% | 1161 |
|
|
2023
Q2 | $231K | Sell |
115,539
-43,164
| -27% | -$86.3K | ﹤0.01% | 1160 |
|
|
2023
Q1 | $333K | Buy |
+158,703
| New | +$333K | ﹤0.01% | 988 |
|
|
2016
Q4 | – | Sell |
-5,070
| Closed | -$29K | – | 963 |
|
|
2016
Q3 | $29K | Hold |
5,070
| – | – | ﹤0.01% | 817 |
|
|
2016
Q2 | $32K | Sell |
5,070
-60
| -1% | -$379 | ﹤0.01% | 846 |
|
|
2016
Q1 | $43K | Hold |
5,130
| – | – | ﹤0.01% | 803 |
|
|
2015
Q4 | $52K | Buy |
5,130
+1,340
| +35% | +$13.6K | ﹤0.01% | 784 |
|
|
2015
Q3 | $45K | Buy |
3,790
+2,010
| +113% | +$23.9K | ﹤0.01% | 693 |
|
|
2015
Q2 | $35K | Buy |
+1,780
| New | +$35K | ﹤0.01% | 613 |
|
|
2013
Q4 | – | Sell |
-5,050
| Closed | -$235K | – | 750 |
|
|
2013
Q3 | $235K | Buy |
5,050
+540
| +12% | +$25.1K | ﹤0.01% | 446 |
|
|
2013
Q2 | $234K | Buy |
+4,510
| New | +$234K | ﹤0.01% | 457 |
|